FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation

On January 9, 2020, FDA approved avapritinib (AYVAKITTM, Blueprint Medicines Corporation) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations.

Source: FDA Center for Drug Evaluation and Research - What's New - January 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news